Skip to main content
Premium Trial:

Request an Annual Quote

UgenTec, LGC Biosearch Technologies to Launch Coronavirus Detection Workflow

NEW YORK — Belgian molecular diagnostics software developer UgenTec has partnered with LGC Biosearch Technologies to launch an artificial intelligence-based workflow for the detection of the 2019-nCoV coronavirus, the companies said on Wednesday.

Specific terms of the alliance were not disclosed.

According to the companies, the research-use-only workflow is based on UgenTec's flagship FastFinder PCR diagnostics software platform and Biosearch's reagents. The workflow is compatible with common PCR devices and can transfer de-identified and anonymized test results to disease control organizations.

"In times like these, labs have to respond to crises fast and handle increasing volumes of samples with existing personnel," UgenTec CEO Steven Verhoeven said in a statement. "With our software, labs are able to standardize the interpretation of results and simplify the communication with government disease centers."

Biosearch, a subsidiary of London-based LGC, recently began expediting availability of its Black Hole and Blackberry Quenchers and other dyes and components for use in 2019-nCoV diagnostic kits.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.